Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
US Department of Justice
Johnson and Johnson
Baxter
Moodys
Harvard Business School
Cantor Fitzgerald
US Army
Farmers Insurance

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,894,051

« Back to Dashboard

Which drugs does patent 6,894,051 protect, and when does it expire?

Patent 6,894,051 protects GLEEVEC and is included in two NDAs.

Protection for GLEEVEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-one countries.
Summary for Patent: 6,894,051
Title: Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Abstract:The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
Inventor(s): Zimmermann; Jurg (Basel, CH), Sutter; Bertrand (Hesingue, FR), Burger; Hans Michael (Allschwil, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/463,097
Patent Claim Types:
see list of patent claims
Compound; Composition; Process; Use;

Drugs Protected by US Patent 6,894,051

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-001 May 10, 2001 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-002 May 10, 2001 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-001 Apr 18, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-002 Apr 18, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,894,051

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1764/97Jul 18, 1997
PCT Information
PCT FiledJuly 16, 1998PCT Application Number:PCT/EP98/04427
PCT Publication Date:January 28, 1999PCT Publication Number: WO99/03854

Non-Orange Book US Patents Family Members for Patent 6,894,051

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,151,106 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use ➤ Subscribe
7,544,799 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use ➤ Subscribe
RE43932 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,894,051

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016351 ➤ Subscribe
Argentina 043266 ➤ Subscribe
Austria 251152 ➤ Subscribe
Australia 740713 ➤ Subscribe
Australia 8975998 ➤ Subscribe
Brazil 9810920 ➤ Subscribe
Canada 2296604 ➤ Subscribe
Canada 2622808 ➤ Subscribe
China 1134430 ➤ Subscribe
China 1264375 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
Novartis
Harvard Business School
Daiichi Sankyo
Johnson and Johnson
Merck
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot